Sun Pharma.Inds.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE044A01036
  • NSEID: SUNPHARMA
  • BSEID: 524715
INR
1,756.35
-21.1 (-1.19%)
BSENSE

Mar 23

BSE+NSE Vol: 28.34 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Lupin
Torrent Pharma
Sun Pharma.Inds.
Aurobindo Pharma
Biocon
Dr Reddy's Labs
Zydus Lifesci.
Alkem Lab
Divi's Lab.
Mankind Pharma
Cipla

Why is Sun Pharmaceutical Industries Ltd ?

1
Low Debt Company with Strong Long Term Fundamental Strength
  • Healthy long term growth as Net Sales has grown by an annual rate of 11.37% and Operating profit at 20.79%
  • Company has a low Debt to Equity ratio (avg) at 0 times
  • The company has been able to generate a Return on Equity (avg) of 15.21% signifying high profitability per unit of shareholders funds
2
The company has declared Positive results for the last 3 consecutive quarters
  • INVENTORY TURNOVER RATIO(HY) Highest at 5.21 times
  • CASH AND CASH EQUIVALENTS(HY) Highest at Rs 12,257.42 cr
  • NET SALES(Q) Highest at Rs 15,520.54 cr
3
High Institutional Holdings at 36.94%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
With its market cap of Rs 4,26,410 cr, it is the biggest company in the sector and constitutes 18.37% of the entire sector
  • Its annual Sales of Rs 56,809.09 are 12.02% of the industry
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Sun Pharma.Inds. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sun Pharma.Inds. for you?

Low Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Sun Pharma.Inds.
-1.54%
-0.08
19.03%
Sensex
-5.47%
-0.43
12.65%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
11.37%
EBIT Growth (5y)
20.79%
EBIT to Interest (avg)
55.35
Debt to EBITDA (avg)
0.28
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.71
Tax Ratio
25.78%
Dividend Payout Ratio
35.13%
Pledged Shares
0.97%
Institutional Holding
36.94%
ROCE (avg)
21.14%
ROE (avg)
15.21%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
35
Industry P/E
32
Price to Book Value
5.48
EV to EBIT
27.53
EV to EBITDA
23.08
EV to Capital Employed
7.32
EV to Sales
7.11
PEG Ratio
11.92
Dividend Yield
0.93%
ROCE (Latest)
25.07%
ROE (Latest)
14.84%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
INVENTORY TURNOVER RATIO(HY)

Highest at 5.21 times

CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 12,257.42 cr

NET SALES(Q)

Highest at Rs 15,520.54 cr

PBDIT(Q)

Highest at Rs 4,948.49 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 31.88%

PBT LESS OI(Q)

Highest at Rs 4,137.80 cr.

PAT(Q)

Highest at Rs 3,762.64 cr.

EPS(Q)

Highest at Rs 14.04

-2What is not working for the Company
DEBTORS TURNOVER RATIO(HY)

Lowest at 3.54 times

Loading Valuation Snapshot...

Here's what is working for Sun Pharma.Inds.

Inventory Turnover Ratio- Half Yearly
Highest at 5.21 times and Grown
each half year in the last five half yearly periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Net Sales - Quarterly
Highest at Rs 15,520.54 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 4,948.49 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 31.88%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 4,137.80 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 4,137.80 cr has Grown at 22.1% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 3,388.53 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 3,762.64 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 3,762.64 cr has Grown at 30.3% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 2,887.24 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 14.04
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Cash and Cash Equivalents - Half Yearly
Highest at Rs 12,257.42 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Sun Pharma.Inds.

Debtors Turnover Ratio- Half Yearly
Lowest at 3.54 times
in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio